» Articles » PMID: 39749698

SUCLG1 Promotes Aerobic Respiration and Progression in Plexiform Neurofibroma

Overview
Journal Int J Oncol
Specialty Oncology
Date 2025 Jan 3
PMID 39749698
Authors
Affiliations
Soon will be listed here.
Abstract

Plexiform neurofibromas (PNFs) are benign tumors that affect 20‑50% of patients with type I neurofibromatosis (NF1). PNF carries a risk of malignancy. There is no effective cure for PNF. Its onset may be associated with genetic and metabolic abnormalities, but the exact mechanisms remain unclear. Succinate‑CoA ligase GDP/ADP‑Forming Subunit α(SUCLG1), a catalytic enzyme in the tricarboxylic acid cycle, is highly expressed in PNF. The present study aimed to explore the role of SUCLG1 in function and metabolism of PNF cells. SUCLG1 expression was verified using western blotting and immunofluorescence. After inducing SUCLG1 knockdown and overexpression, functional changes in PNF cells were assessed, as well as effects of SUCLG1 on cell respiration and glucose metabolism. Quantitative PCR, WB, electron microscopy and Flow cytometry demonstrated that SUCLG1 enhanced mitochondrial quality and promoted mitochondrial fusion, thereby driving proliferation and migration of tumor cells, inhibiting apoptosis and altering the cell cycle. A Seahorse assay showed that elevated SUCLG1 expression enhanced cell aerobic respiration without affecting the glycolytic process. This suggests that SUCLG1 upregulation in PNF does not trigger the Warburg effect associated with malignant tumors. This study also demonstrated the positive regulation of cellular function by promoting the expression level of the gene when SUCLG1 expression was elevated. In conclusion, SUCLG1 altered the mechanism of mitochondrial quality control to enhance cell aerobic respiration, thereby driving the pathogenesis of PNF. Thus, SUCLG1 can serve as a potential target in future therapeutic strategies.

References
1.
Well L, Dobel K, Kluwe L, Bannas P, Farschtschi S, Adam G . Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth. PLoS Genet. 2021; 17(5):e1009517. PMC: 8099117. DOI: 10.1371/journal.pgen.1009517. View

2.
Rizzo D, Ruggiero A, Amato M, Maurizi P, Riccardi R . BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities. Expert Opin Drug Metab Toxicol. 2016; 12(12):1397-1405. DOI: 10.1080/17425255.2016.1214710. View

3.
Weiss B, Wolters P, Plotkin S, Widemann B, Tonsgard J, Blakeley J . NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021; 39(7):797-806. PMC: 8078274. DOI: 10.1200/JCO.20.02220. View

4.
Dombi E, Baldwin A, Marcus L, Fisher M, Weiss B, Kim A . Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016; 375(26):2550-2560. PMC: 5508592. DOI: 10.1056/NEJMoa1605943. View

5.
Bernier A, Larbrisseau A, Perreault S . Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature. Pediatr Neurol. 2016; 60:24-29.e1. DOI: 10.1016/j.pediatrneurol.2016.03.003. View